Consistently, FGF2 blunted the cytotoxicity and retardation of cell proliferation induced by the FLT3 inhibitor, quizartinib, after drug removal in MOLM-14, a human AML cell line carrying an FLT3 internal tandem duplication mutation (FLT3-ITD; Fig. 4A and B). Here, FGF2 is linked to acute myeloid leukemia.